Clinical pharmacokinetics and dose optimisation of carboplatin.
about
Impaired Brain Dopamine and Serotonin Release and Uptake in Wistar Rats Following Treatment with CarboplatinInvestigation of the spatiotemporal responses of nanoparticles in tumor tissues with a small-scale mathematical modelDose schedule optimization and the pharmacokinetic driver of neutropeniaCarboplatin-associated ototoxicity in children with retinoblastoma.Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment.Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients.A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activityCarboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions.Effects of renal function on pharmacokinetics of recombinant human granulocyte colony-stimulating factor in lung cancer patients.Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.A dynamic magnetic shift method to increase nanoparticle concentration in cancer metastases: a feasibility study using simulations on autopsy specimens.Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.Superselective Intra-arterial Infusion Chemotherapy with Nedaplatin for Oral Cancer: A Pharmacological Study of the Dose Clearance.Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursOptimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans.Treatment and outcome of four cats with apocrine gland carcinoma of the anal sac and review of the literature.A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer.Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.Carboplatin loaded polymethylmethacrylate nano-particles in an adjunctive role in retinoblastoma: an animal trial.Efficacy and safety of modified rituximab-ESHAP therapy for relapsed/refractory B-cell lymphoma.Pharmacokinetics and hematotoxicity of a novel copper-based anticancer agent: casiopeina III-Ea, after a single intravenous dose in rats.Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future.Clinical trial of blood-brain barrier disruption by pulsed ultrasound.Safety and efficacy of posterior sub-Tenon's carboplatin injection versus intravitreal melphalan therapy in the management of retinoblastoma with secondary vitreous seeds.
P2860
Q27300384-104F58B7-0642-4683-AC0B-7824C20F4333Q28485922-8A81AB56-FEF8-442B-947F-F3EEE1E1D97BQ28544635-B6ED72F0-171C-4390-BF9B-3CF2E4EF44B5Q30513911-8FF88344-380E-4ECA-A520-EC3DC429BEF5Q33315395-EA0FE342-ACD5-4AD6-BE4F-A6EBA453B0B2Q33370887-47A5ED87-9675-40C2-BA65-CDD5447929BEQ33396073-6081D393-F58F-440C-8C71-281154ACC993Q33399785-B1F2462F-123C-4F16-9720-F2DACC14AB3DQ33421343-964B9CEC-1274-47AF-9129-F3463DBC2260Q33436456-D61F9021-C2DD-411C-A39B-1546A6305EAFQ33982472-62CFC42C-4AA3-4BBF-BDB6-BC29E85FF72AQ35053993-22E0B376-8B48-43E7-9667-BD697BA7ED30Q35574714-5C875129-A227-4DAB-A76C-34DAE085E4F8Q35825455-EA7FE05E-AD66-40B8-8731-1395B09DE93BQ35880907-0C78FB09-E492-4CF9-97BD-C6A8EB6544BEQ36387910-1A9EE315-3358-4BFD-B3DC-94CBE2843B9BQ36488198-18E3BC29-4750-41B1-BF8D-5891FEFB34EBQ37344425-7E41F17E-FB22-4D9A-9892-19391EEF597EQ37904488-72E8E32E-679A-41DD-A2D7-E09E93B60831Q38706298-A6575C20-ABDE-4C28-B606-2CBA2466AE25Q38728212-9C49DAB1-1F22-44EB-A947-380E2FCDFD46Q40954188-001652E4-6F6C-4D3F-85FA-BAE19E1C3CE2Q43130392-2412E969-B095-4BC1-B4B1-62F1904A4CF2Q44103442-8F1F8724-AB60-4633-9464-9AB40D8C8AE2Q47943868-47B973E4-3CA6-41F0-87E2-A4644127267CQ48674887-D309865A-F3B6-40A1-9C61-A464867AE913Q52620218-18674857-0897-47B9-92BC-CEC41F4946BB
P2860
Clinical pharmacokinetics and dose optimisation of carboplatin.
description
1997 nî lūn-bûn
@nan
1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Clinical pharmacokinetics and dose optimisation of carboplatin.
@ast
Clinical pharmacokinetics and dose optimisation of carboplatin.
@en
type
label
Clinical pharmacokinetics and dose optimisation of carboplatin.
@ast
Clinical pharmacokinetics and dose optimisation of carboplatin.
@en
prefLabel
Clinical pharmacokinetics and dose optimisation of carboplatin.
@ast
Clinical pharmacokinetics and dose optimisation of carboplatin.
@en
P1476
Clinical pharmacokinetics and dose optimisation of carboplatin
@en
P2093
S B Duffull
P304
P356
10.2165/00003088-199733030-00002
P577
1997-09-01T00:00:00Z
P6179
1032127963